Literature DB >> 20807702

TRAIL-expressing CD8+ T cells mediate tolerance following soluble peptide-induced peripheral T cell deletion.

Prajwal Gurung1, Tamara A Kucaba, Stephen P Schoenberger, Thomas A Ferguson, Thomas S Griffith.   

Abstract

Peripheral tolerance controls the action of self-reactive T cells that escape thymic deletion. We showed previously that deletion of Ag-specific CD4+ T cells induced a CD8+ T(reg) population that maintained tolerance by deleting T cells with the same Ag specificity. The present study explored the mechanism of action of these CD8+ T(reg). Following OT-II T cell deletion by soluble OVA₃₂₃₋₃₃₉, B6 mice were unresponsive to challenge after CFA/OVA immunization, and Trail⁻/⁻ or Dr5⁻/⁻ mice were immune, although all strains displayed similar OT-II peripheral deletion. Interestingly, B6 mice remained tolerant to OVA even after a second infusion of OT-II T cells. Tolerance could be transferred to naïve recipients using CD8+ T cells from B6 or Dr5⁻/⁻ mice that experienced peptide-induced peripheral OT-II deletion but not from Trail⁻/⁻ mice. Subsequent investigation found that the mechanism of action of the CD8+ T(reg) was TRAIL-mediated OT-II T cell deletion in a TCR-specific manner. Furthermore, the tolerance was transient, as it was established by 14 days after peptide injection but lost by Day 56. Together, these data provide evidence to suggest that the mechanism behind transient peripheral tolerance induced following T cell deletion is the cytotoxic activity of TRAIL-expressing CD8+ T(reg).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20807702      PMCID: PMC2996898          DOI: 10.1189/jlb.0610343

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  62 in total

Review 1.  Apoptosis, tolerance, and regulatory T cells--old wine, new wineskins.

Authors:  Thomas A Ferguson; Patrick M Stuart; John M Herndon; Thomas S Griffith
Journal:  Immunol Rev       Date:  2003-06       Impact factor: 12.988

2.  Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides.

Authors:  M D Howell; S T Winters; T Olee; H C Powell; D J Carlo; S W Brostoff
Journal:  Science       Date:  1989-11-03       Impact factor: 47.728

3.  Sepsis-induced apoptosis leads to active suppression of delayed-type hypersensitivity by CD8+ regulatory T cells through a TRAIL-dependent mechanism.

Authors:  Jacqueline Unsinger; Hirotaka Kazama; Jacqueline S McDonough; Thomas S Griffith; Richard S Hotchkiss; Thomas A Ferguson
Journal:  J Immunol       Date:  2010-05-12       Impact factor: 5.422

4.  Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis.

Authors:  A A Vandenbark; G Hashim; H Offner
Journal:  Nature       Date:  1989-10-12       Impact factor: 49.962

5.  Anti-idiotypic network induced by T cell vaccination against experimental autoimmune encephalomyelitis.

Authors:  O Lider; T Reshef; E Beraud; A Ben-Nun; I R Cohen
Journal:  Science       Date:  1988-01-08       Impact factor: 47.728

6.  Kinetic differences in unresponsiveness of thymus and bone marrow cells.

Authors:  J M Chiller; G S Habicht; W O Weigle
Journal:  Science       Date:  1971-02-26       Impact factor: 47.728

7.  Suppression of experimentally induced autoimmune encephalomyelitis by cytolytic T-T cell interactions.

Authors:  D Sun; Y Qin; J Chluba; J T Epplen; H Wekerle
Journal:  Nature       Date:  1988-04-28       Impact factor: 49.962

8.  Induction of suppressor cells by staphylococcal enterotoxin B: identification of a suppressor cell circuit in the generation of suppressor-effector cells.

Authors:  M Holly; Y S Lin; T J Rogers
Journal:  Immunology       Date:  1988-08       Impact factor: 7.397

9.  Infectious immunological tolerance.

Authors:  R K Gershon; K Kondo
Journal:  Immunology       Date:  1971-12       Impact factor: 7.397

10.  Dual immunological unresponsiveness induced by cell membrane coupled hapten or antigen.

Authors:  J R Battisto; B R Bloom
Journal:  Nature       Date:  1966-10-08       Impact factor: 49.962

View more
  11 in total

Review 1.  Armed response: how dying cells influence T-cell functions.

Authors:  Thomas A Ferguson; Jayoung Choi; Douglas R Green
Journal:  Immunol Rev       Date:  2011-05       Impact factor: 12.988

Review 2.  Cell death in the maintenance and abrogation of tolerance: the five Ws of dying cells.

Authors:  Thomas S Griffith; Thomas A Ferguson
Journal:  Immunity       Date:  2011-10-28       Impact factor: 31.745

Review 3.  Impact of sepsis on CD4 T cell immunity.

Authors:  Javier Cabrera-Perez; Stephanie A Condotta; Vladimir P Badovinac; Thomas S Griffith
Journal:  J Leukoc Biol       Date:  2014-05-02       Impact factor: 4.962

4.  Systemic immunological tolerance to ocular antigens is mediated by TRAIL-expressing CD8+ T cells.

Authors:  Thomas S Griffith; Erik L Brincks; Prajwal Gurung; Tamara A Kucaba; Thomas A Ferguson
Journal:  J Immunol       Date:  2010-12-17       Impact factor: 5.422

5.  Immune unresponsiveness to secondary heterologous bacterial infection after sepsis induction is TRAIL dependent.

Authors:  Prajwal Gurung; Deepa Rai; Stephanie A Condotta; Jeffrey C Babcock; Vladimir P Badovinac; Thomas S Griffith
Journal:  J Immunol       Date:  2011-07-25       Impact factor: 5.422

Review 6.  Therapeutic applications of TRAIL receptor agonists in cancer and beyond.

Authors:  Gustavo P Amarante-Mendes; Thomas S Griffith
Journal:  Pharmacol Ther       Date:  2015-09-05       Impact factor: 12.310

Review 7.  T-cell-mediated immunity and the role of TRAIL in sepsis-induced immunosuppression.

Authors:  Stephanie A Condotta; Javier Cabrera-Perez; Vladimir P Badovinac; Thomas S Griffith
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

Review 8.  Interactions of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) with the Immune System: Implications for Inflammation and Cancer.

Authors:  Katharina Beyer; Ann-Kathrin Baukloh; Ani Stoyanova; Carsten Kamphues; Arne Sattler; Katja Kotsch
Journal:  Cancers (Basel)       Date:  2019-08-13       Impact factor: 6.639

9.  Advances in Viral Vector-Based TRAIL Gene Therapy for Cancer.

Authors:  Lyse A Norian; Britnie R James; Thomas S Griffith
Journal:  Cancers (Basel)       Date:  2011-02-10       Impact factor: 6.639

Review 10.  The Emerging Jamboree of Transformative Therapies for Autoimmune Diseases.

Authors:  José M Carballido; Camille Regairaz; Celine Rauld; Layla Raad; Damien Picard; Michael Kammüller
Journal:  Front Immunol       Date:  2020-03-31       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.